ArticleCancer research and treatment2019
Validation of the Eighth American Joint Committee on Cancer Staging System for Distal Bile Duct Carcinoma.
Article in Cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The consistencies and inconsistencies between distal cholangiocarcinoma and pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Outcome of resectable distal cholangiocarcinoma in a single-centre Western patient cohort: comparison of the 7th and 8th edition of the UICC/AJCC TNM classification.Acta oncologica (Stockholm, Sweden) · 2026Article
- Histologic patterns of venous invasion in distal extrahepatic bile duct carcinoma correlate with prognosis.Virchows Archiv : an international journal of pathology · 2026Article
- Article
- Improved prognostic predictability of the latest Japanese TNM Classification in patients undergoing resection for distal cholangiocarcinoma.Global health & medicine · 2025Article
- Effect of MELD-Na score on overall survival of periampullary cancer.Updates in surgery · 2024Article
- Clinical impact of pancreatic invasion in T1-stage distal bile duct cancer and prognostic factors associated with long-term survival: A multicenter study.Journal of hepato-biliary-pancreatic sciences · 2024Article
- The prognostic value of the number of metastatic lymph nodes on the long-term survival of intrahepatic cholangiocarcinoma using the SEER database.Journal of gastrointestinal oncology · 2023Article
- Retrospective analysis of 8th edition American Joint Cancer Classification: Distal cholangiocarcinoma.Annals of hepato-biliary-pancreatic surgery · 2023Article
- Proposal for a new N-stage classification system for intrahepatic cholangiocarcinoma.Frontiers in oncology · 2023Article
- Metachronous pancreatic cancer 18 years after resection of common bile duct cancer: A case report.Frontiers in surgery · 2022Article
- Prognostic significance of tumor-infiltrating lymphocytes in predicting outcome of distal cholangiocarcinoma in Thailand.Frontiers in oncology · 2022Article
- Prognostic Significance of Growth Pattern in Predicting Outcome ofFrontiers in public health · 2022Article
- Prognostic Factors of Long-term Survival Following Radical Resection for Ampullary Carcinoma.Journal of gastrointestinal cancer · 2021Article
- Intra-pancreatic distal cholangiocarcinoma and pancreatic ductal adenocarcinoma: a common short and long-term prognosis?Updates in surgery · 2021Article
- Surgical management of biliary malignancy.Current problems in surgery · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeT category of the eighth edition of the American Joint Committee on Cancer (AJCC) staging system for distal bile duct carcinoma (DBDC) was changed to include tumor invasion depth measurement, while the N category adopted a 3-tier classification system based on the number of metastatic nodes. MATERIALS AND
methodsTo validate cancer staging, a total of 200 surgically resected DBDCs were staged and compared according to the seventh and eighth editions.
resultsT categories included T1 (n=37, 18.5%), T2 (n=114, 57.0%), and T3 (n=49, 24.5%). N categories included N0 (n=133, 66.5%), N1 (n=50, 25.0%), and N2 (n=17, 8.5%). Stage groupings included I (n=33, 16.5%), II (n=150, 75.0%), and III (n=17, 8.5%). The overall 5-year survival rates (5-YSRs) of T1, T2, and T3 were 59.3%, 42.4%, and 12.2%, respectively. T category could discriminate patient survival by both pairwise (T1 and T2, p=0.011; T2 and T3, p < 0.001) and overall (p < 0.001) comparisons. The overall 5-YSRs of N0, N1, and N2 were 47.3%, 17.0%, and 14.7%, respectively. N category could partly discriminate patient survival by both pairwise (N0 and N1, p < 0.001; N1 and N2, p=0.579) and overall (p < 0.001) comparisons. The overall 5-YSRs of stages I, II, and III were 59.0%, 35.4%, and 14.7%, respectively. Stages could distinguish patient survival by both pairwise (I and II, p=0.002; II and III, p=0.015) and overall (p < 0.001) comparisons. On multivariate analyses, T and N categories (p=0.014 and p=0.029) and pancreatic invasion (p=0.006) remained significant prognostic factors.
conclusionThe T andNcategories of the eighth edition AJCC staging system for DBDC accurately predict patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.